NewAmsterdam Pharma Co paid its 5 named executives $30.8M in total in FY2025 (Dec). CEO Michael Davidson was paid $13.6M of that.
Pay$100 in the stock at the end of FY23 → $314
Pay of each named executive
Michael DavidsonChief Executive Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | Not disclosed |
2 years
Douglas KlingChief Operating Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | Not disclosed |
2 years
John Kastelein, M.D., Ph.D. FESCChief Scientific Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | Not disclosed |
3 years
Ian SomaiyaChief Financial Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | Not disclosed |
2 years
Louise KooijChief Accounting Officer
| FY2025 (Dec) |
1 year
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $10.6M. The CEO of NewAmsterdam Pharma Co was paid $13.6M, 29% above the median.
- 1Scholar Rock Holding
- 2Cogent Biosciences
- 3Viking Therapeutics
- 4Madrigal Pharmaceuticals
- 5NewAmsterdam Pharma CoThis company
- 6Immunovant
- 7Krystal Biotech
- 8IDEAYA Biosciences
- 9Structure Therapeutics
- 10Vera Therapeutics
- 11Tarsus Pharmaceuticals
- 124D Molecular Therapeutics, Inc.Not disclosed
- 1389bio, Inc.Not disclosed
- 14Akero Therapeutics, Inc.Not disclosed
- 15Belite Bio, Inc.Not disclosed
- 16BiohavenNot disclosed
- 17Crinetics Pharmaceuticals, Inc.Not disclosed
- 18Cullinan Oncology, Inc.Not disclosed
- 19GeronNot disclosed
- 20Humacyte, Inc.Not disclosed
- 21Iovance Biotherapeutics, Inc.Not disclosed
- 22Keros Therapeutics, Inc.Not disclosed
- 23Pliant Therapeutics, Inc.Not disclosed
- 24SpringWorks Therapeutics, Inc.Not disclosed
- 25Summit TherapeuticsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.